Relay Therapeutics (RLAY) News Today $4.50 -0.34 (-7.02%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Sold by HighTower Advisors LLCHighTower Advisors LLC cut its position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 48.9% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 154,920 shares of the company's stock after selling 148,425 shares during the quDecember 18 at 3:34 AM | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Shares Down 5.4% - Here's What HappenedRelay Therapeutics (NASDAQ:RLAY) Stock Price Down 5.4% - Should You Sell?December 17 at 3:10 PM | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Recommendation of "Moderate Buy" from BrokeragesRelay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the eleven brokerages that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and ten have issuDecember 17 at 2:21 AM | marketbeat.comRelay Therapeutics, Inc. (RLAY): A Bull Case TheoryDecember 13, 2024 | insidermonkey.comJefferies Reaffirms Their Buy Rating on Relay Therapeutics (RLAY)December 13, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Relay Therapeutics (RLAY)December 12, 2024 | markets.businessinsider.comRelay Therapeutics (RLAY) Gets a Buy from BarclaysDecember 12, 2024 | markets.businessinsider.comJMP Securities Reiterates Market Outperform Rating for Relay Therapeutics (NASDAQ:RLAY)JMP Securities reissued a "market outperform" rating and set a $21.00 price target on shares of Relay Therapeutics in a research note on Thursday.December 12, 2024 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Shares Acquired by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. boosted its holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 26.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,035,789 shares of the company's stock after purchDecember 12, 2024 | marketbeat.comRelay Therapeutics Reports Promising Data on RLY-2608December 11, 2024 | markets.businessinsider.comRelay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free SurvivalDecember 11, 2024 | globenewswire.comRelay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer SymposiumDecember 9, 2024 | globenewswire.comPoint72 Asset Management L.P. Invests $9.55 Million in Relay Therapeutics, Inc. (NASDAQ:RLAY)Point72 Asset Management L.P. purchased a new position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund purchased 1,349,400 shares of the company's stock, valued at approximately $9,554,00December 8, 2024 | marketbeat.comLeerink Partnrs Has Strong Estimate for RLAY FY2024 EarningsDecember 8, 2024 | americanbankingnews.comWhat is HC Wainwright's Estimate for RLAY FY2024 Earnings?Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) - HC Wainwright lowered their FY2024 earnings per share (EPS) estimates for Relay Therapeutics in a research report issued on Wednesday, December 4th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($2.47)December 6, 2024 | marketbeat.comFY2024 Earnings Forecast for RLAY Issued By Leerink PartnrsRelay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) - Stock analysts at Leerink Partnrs raised their FY2024 EPS estimates for shares of Relay Therapeutics in a report issued on Tuesday, December 3rd. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings per shareDecember 6, 2024 | marketbeat.comRelay Therapeutics, Elevar Therapeutics enter licensing agreementDecember 4, 2024 | markets.businessinsider.comMaven Securities LTD Makes New Investment in Relay Therapeutics, Inc. (NASDAQ:RLAY)Maven Securities LTD bought a new stake in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 337,426 shares of the company's stock, valued atDecember 4, 2024 | marketbeat.comElevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid TumorsDecember 3, 2024 | globenewswire.comRelay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid TumorsDecember 3, 2024 | globenewswire.comRelay Therapeutics Has Interesting Science That Needs To Be Proven In TrialsDecember 1, 2024 | seekingalpha.comBellevue Group AG Has $52.23 Million Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY)Bellevue Group AG lifted its position in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 15.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,377,184 shares of the company'December 1, 2024 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Shares Acquired by Walleye Capital LLCWalleye Capital LLC lifted its holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 6,659.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,819,983 shares of the company's stock after puNovember 30, 2024 | marketbeat.comBraidwell LP Buys 492,628 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)Braidwell LP grew its stake in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 16.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,499,427 shares of the company's stock after acquiringNovember 29, 2024 | marketbeat.comEventide Asset Management LLC Buys New Shares in Relay Therapeutics, Inc. (NASDAQ:RLAY)Eventide Asset Management LLC purchased a new position in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 2,682,083 shares of the company's stocNovember 29, 2024 | marketbeat.comSio Capital Management LLC Acquires Shares of 945,839 Relay Therapeutics, Inc. (NASDAQ:RLAY)Sio Capital Management LLC bought a new position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 945,839 shares of the company's stock, valued at apNovember 29, 2024 | marketbeat.comAlly Bridge Group NY LLC Invests $4.43 Million in Relay Therapeutics, Inc. (NASDAQ:RLAY)Ally Bridge Group NY LLC purchased a new stake in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 626,058 shares of the company's stock, valued at approximately $4,43November 28, 2024 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Rating of "Moderate Buy" by BrokeragesRelay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) has received a consensus rating of "Moderate Buy" from the ten brokerages that are covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 1-yNovember 22, 2024 | marketbeat.comFirst Turn Management LLC Acquires Shares of 1,226,354 Relay Therapeutics, Inc. (NASDAQ:RLAY)First Turn Management LLC acquired a new stake in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 1,226,354 shares of the company's stock, valued atNovember 19, 2024 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Stock Price Down 4.8% - Time to Sell?Relay Therapeutics (NASDAQ:RLAY) Trading Down 4.8% - Here's WhyNovember 15, 2024 | marketbeat.comFY2024 Earnings Estimate for RLAY Issued By Leerink PartnrsRelay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) - Investment analysts at Leerink Partnrs upped their FY2024 earnings per share (EPS) estimates for shares of Relay Therapeutics in a report released on Wednesday, November 6th. Leerink Partnrs analyst A. Berens now forecasts that the company wiNovember 11, 2024 | marketbeat.comHC Wainwright Boosts Relay Therapeutics (NASDAQ:RLAY) Price Target to $20.00HC Wainwright lifted their price objective on shares of Relay Therapeutics from $19.00 to $20.00 and gave the company a "buy" rating in a research note on Friday.November 8, 2024 | marketbeat.comPromising Pipeline and Financial Stability Drive Buy Rating for Relay TherapeuticsNovember 8, 2024 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on Relay Therapeutics (RLAY)November 7, 2024 | markets.businessinsider.comBuy Rating on Relay Therapeutics: Promising Developments and Strong Financial PositionNovember 7, 2024 | markets.businessinsider.comRelay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate HighlightsNovember 6, 2024 | globenewswire.comRelay Therapeutics (RLAY) Scheduled to Post Earnings on WednesdayRelay Therapeutics (NASDAQ:RLAY) will be releasing earnings after the market closes on Wednesday, November 6, Zacks reports.October 31, 2024 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 6,802 SharesOctober 31, 2024 | insidertrades.comRelay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024October 30, 2024 | globenewswire.comInstitutional owners may consider drastic measures as Relay Therapeutics, Inc.'s (NASDAQ:RLAY) recent US$67m drop adds to long-term lossesOctober 28, 2024 | finance.yahoo.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Rating of "Moderate Buy" from AnalystsShares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) have earned an average rating of "Moderate Buy" from the ten analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and nine have issued a buy rating onOctober 28, 2024 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Short Interest UpdateRelay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) was the recipient of a significant increase in short interest in September. As of September 30th, there was short interest totalling 12,370,000 shares, an increase of 24.7% from the September 15th total of 9,920,000 shares. Based on an average trading volume of 1,910,000 shares, the days-to-cover ratio is currently 6.5 days.October 15, 2024 | marketbeat.comBuy Rating for Relay Therapeutics: Promising Pipeline and Positive PI3Ka Inhibitor ProspectsOctober 15, 2024 | markets.businessinsider.comRelay Therapeutics (NASDAQ:RLAY) Receives Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $19.00 target price on shares of Relay Therapeutics in a research note on Monday.October 14, 2024 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Sees Unusually-High Trading Volume - Still a Buy?Relay Therapeutics (NASDAQ:RLAY) Sees Strong Trading Volume - Still a Buy?October 11, 2024 | marketbeat.comMillennium Management LLC Acquires 921,271 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)Millennium Management LLC grew its position in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 404.2% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,149,177 shares of the company's stock after buying an additional 921,271October 10, 2024 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Shares Down 4% - Here's WhyRelay Therapeutics (NASDAQ:RLAY) Stock Price Down 4% - Time to Sell?October 9, 2024 | marketbeat.comThrivent Financial for Lutherans Acquires Shares of 120,011 Relay Therapeutics, Inc. (NASDAQ:RLAY)Thrivent Financial for Lutherans acquired a new stake in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 120,011 shares of the company's stock, valued at apOctober 8, 2024 | marketbeat.com144,986 Shares in Relay Therapeutics, Inc. (NASDAQ:RLAY) Acquired by Squarepoint Ops LLCSquarepoint Ops LLC purchased a new position in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 144,986 shares of the company's stock, valued at approximately $October 7, 2024 | marketbeat.comMarshall Wace LLP Purchases New Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY)Marshall Wace LLP acquired a new stake in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 276,702 shares of the company's stock, valued atOctober 6, 2024 | marketbeat.com Get Relay Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter. Email Address This Crypto Is Set to Explode in December (Ad)Discover our #1 crypto for the Trump Presidency Bull Run now! (Available for a Short Time) We highly recommend this hot altcoin before prices get too high Check it out by going here now RLAY Media Mentions By Week RLAY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RLAY News Sentiment▼0.560.72▲Average Medical News Sentiment RLAY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RLAY Articles This Week▼114▲RLAY Articles Average Week Get Relay Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies JANX News EWTX News XENE News MRUS News TWST News ACAD News MOR News VCEL News ZLAB News SWTX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RLAY) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relay Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
